Biotechnology · Chapel Hill, North Carolina, United States
$18.53
+2.94% (+$0.53)2026-07-09
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$15.7M
EPS$-0.35
Market Cap$449.8M
Price Performance
Historical data including institutional events
Company Profile
C
Christopher Giordano
CEO & Executive Director
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
